Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $16,149.24 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 684 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $23.61, for a total value of $16,149.24. Following the transaction, the insider owned 120,466 shares of the company’s stock, valued at $2,844,202.26. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, March 2nd, Patrick Burnett sold 6,287 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.18, for a total value of $158,306.66.

Arcutis Biotherapeutics Stock Performance

Shares of NASDAQ ARQT opened at $21.17 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.99 and a debt-to-equity ratio of 0.54. Arcutis Biotherapeutics, Inc. has a 12 month low of $12.72 and a 12 month high of $31.77. The stock has a 50 day moving average of $23.65 and a 200-day moving average of $25.77. The company has a market capitalization of $2.65 billion, a P/E ratio of -705.43 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The business had revenue of $105.40 million for the quarter, compared to the consensus estimate of $103.68 million. As a group, equities research analysts predict that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ARQT. TD Cowen boosted their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Mizuho reduced their price target on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Wall Street Zen downgraded Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. HC Wainwright boosted their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of Arcutis Biotherapeutics in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels.
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

Hedge Funds Weigh In On Arcutis Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zevenbergen Capital Investments LLC acquired a new position in Arcutis Biotherapeutics in the 4th quarter valued at $12,140,000. Nordea Investment Management AB acquired a new position in Arcutis Biotherapeutics in the 4th quarter valued at $5,850,000. UBS Group AG raised its holdings in Arcutis Biotherapeutics by 10.0% in the 4th quarter. UBS Group AG now owns 3,243,432 shares of the company’s stock valued at $94,189,000 after acquiring an additional 294,994 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Arcutis Biotherapeutics in the 3rd quarter valued at $4,396,000. Finally, Jennison Associates LLC raised its holdings in Arcutis Biotherapeutics by 10.3% in the 3rd quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after acquiring an additional 1,144,714 shares in the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.